CoChat

Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation

Open access
Seidi, Khaled, Jahanban-Esfahlan, Rana, Zarghami, Nosratollah · 2017 · Tumor Biology

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Abstract

Current vascular targeting strategies pursue two main goals: anti-angiogenesis agents aim to halt sprouting and the formation of new blood vessels, while vascular disrupting agents along with coaguligands seek to compromise blood circulation in the vessels. The ultimate goal of such therapies is to deprive tumor cells out of oxygen and nutrients long enough to succumb cancer cells to death. Most of vascular targeting agents presented promising therapeutic potential, but the final goal which is cure is rarely achieved. Nevertheless, in both preclinical and clinical settings, tumors tend to grow back, featuring a highly invasive, metastatic, and extremely resistant form. This review highlights the critical significance of tumor rim cells as the main factor, determining therapy success with vascular targeting agents. We present an overview of different single and combination treatments with vascular targeting agents that enable efficient targeting of tumor rim cells and long-lasting tumor cure. Understanding the nature of tumor rim cells, how they establish, how they manage to survive of vascular targeting agents, and how they contribute in tumor refractoriness, may open new avenues to the development of beneficial strategies, capable to eliminate residual rim cells, and enable tumor ablation once and forever.

Overview

Integrity signals

Registry

Crossref · 10.1177/1010428317691001

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 116 references

Research works printed but not linked: 19

  1. Tandle A, 2004, J Transl Med, 2, 1
  2. Ran S, 1998, Cancer Res, 58, 4646
  3. Hu P, 2003, Cancer Res, 63, 5046
  4. Seon BK, 1997, Clin Cancer Res, 3, 1031
  5. Matsuno F, 1999, Clin Cancer Res, 5, 371
  6. Halin C, 2003, Cancer Res, 63, 3202
  7. Ciardiello F, 2003, Clin Cancer Res, 9, 1546
  8. Pedley RB, 1996, Cancer Res, 56, 3293
  9. Pedley RB, 2001, Cancer Res, 61, 4716
  10. Green C, 2005, Proc Amer Assoc Cancer Res, 46, 2990
  11. Green C, 2006, Proc Amer Assoc Cancer Res, 47, 514
  12. Kanwar JR, 2001, Cancer Res, 61, 1948
  13. Nilsson F, 2001, Cancer Res, 61, 711
  14. Liu C, 2002, Cancer Res, 62, 5470
  15. Arora N, 1999, Cancer Res, 59, 183
  16. Tijink BM, 2006, J Nucl Med, 47, 1127
  17. Scappaticci FA, 2003, Anticancer Res, 23, 1165
  18. Hou J, 2004, Cell Mol Immunol, 1, 161
  19. Patyar S, 2010, J Biomed Sci, 17, 1

Cited by

See all 43

Metadata

Authors
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N.
Affiliations
  • Tabriz University of Medical Sciences (IR)
  • Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Corresponding author
Zarghami, Nosratollah
Venue
Tumor Biology
Published
2017-03
Volume
39
Issue
3
Pages
101042831769100
ISSN
  • 1010-4283 (ISSN-L)
  • 1423-0380
OpenAlex
W2599903719
Cited by
41
References
115
Citations by year
2026: 4 · 2025: 6 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 2 · 2020: 6 · 2019: 1 · 2018: 5 · 2017: 4
FWCI
0.41
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Tumor Biology (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
University of Tabriz
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords
vascular targeting agents, vascular disrupting agents, tumor resistance, tumor ablation, tumor recurrence, combination therapy, tumor hypoxia
MeSH terms
Blood Vessels, Humans, Neoplasms, Neovascularization, Pathologic, Remission Induction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation. https://app.cochat.ai/papers/10.1177/1010428317691001
The paper
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017). Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation. Tumor Biology. https://doi.org/10.1177/1010428317691001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.